← Leaderboards
John N Clore
Virginia Commonwealth University
$19,895,765
Attributed
$21,498,369
Total exposure
54
Grants
37
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9M · FY2005–14$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$29,447,326 · 56
By mechanism
UL1$25,510,239 · 12
KL2$1,990,000 · 2
M01$1,323,039 · 39
P20$433,912 · 2
R01$190,136 · 1
Top collaborators
- Alan I Green1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Frederick Gerard Moeller$65,095,599
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchInstitutionResearch PersonnelFundingResourcesGrantUnited States National Institutes Of HealthSourceInsulinComputer Retrieval Of Information On Scientific Projects DatabaseHuman SubjectDiabetes MellitusStudentsGlucoseLipidsTranslational ResearchObesityUrineInsulin ResistanceResponseProductionMeasurementInstructionFasting
Grant awards (70)
SYNERGY: The Dartmouth Center for clinical and Translational Science$3,205,208
UL1 · FY2014 · TR
Center for Clinical and Translational Research$3,190,077
UL1 · FY2013 · TR · contact PI
Center for Clinical and Translational Research$497,500
KL2 · FY2013 · TR · contact PI
Center for Clinical and Translational Research$3,650,952
UL1 · FY2012 · TR · contact PI
Center for Clinical and Translational Research$497,500
KL2 · FY2012 · TR · contact PI
Center for Clinical and Translational Research$3,467,475
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$2,739,574
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$507,541
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$507,540
UL1 · FY2011 · RR · contact PI
Center for Clinical and Translational Research$497,500
KL2 · FY2011 · RR · contact PI
Center for Clinical and Translational Research$493,769
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$292,216
UL1 · FY2011 · RR · contact PI
Center for Clinical and Translational Research$268,257
UL1 · FY2011 · RR · contact PI
CENTER FOR CLINICAL AND TRANSLATIONAL RESEARCH$182,630
UL1 · FY2011 · RR · contact PI
Center for Clinical and Translational Research$3,502,500
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$2,294,137
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$499,107
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$499,106
UL1 · FY2010 · RR · contact PI
Center for Clinical and Translational Research$497,500
KL2 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$210,150
UL1 · FY2010 · RR · contact PI
RISK FACTOR ANALYSIS$22,872
M01 · FY2010 · RR · contact PI
THE ROLE OF FATTY ACID COMPOSITION IN ANTI-EPILEPTIC EFFECTS OF THE KETOGENIC$2,577
M01 · FY2010 · RR · contact PI
RENAL GLUCOSE PRODUCTION TO TOTAL GLUCOSE OUTPUT IN PATIENTS$2,094
M01 · FY2010 · RR · contact PI
EFFECTS OF INSTRUCTION ON METABOLIC RISK FACTORS ON LIFESTYLE CHOICES$966
M01 · FY2010 · RR · contact PI
RISK FACTOR ANALYSIS$174,485
M01 · FY2009 · RR · contact PI
THE ROLE OF FATTY ACID COMPOSITION IN ANTI-EPILEPTIC EFFECTS OF THE KETOGENIC$8,398
M01 · FY2009 · RR · contact PI
EFFECTS OF INSTRUCTION ON METABOLIC RISK FACTORS ON LIFESTYLE CHOICES$2,799
M01 · FY2009 · RR · contact PI
RENAL GLUCOSE PRODUCTION TO TOTAL GLUCOSE OUTPUT IN PATIENTS$1,866
M01 · FY2009 · RR · contact PI
THE ROLE OF FATTY ACID COMPOSITION IN RACIAL AND ETHNIC DIFFERENCES IN DM2$150,558
M01 · FY2008 · RR · contact PI
RISK FACTOR ANALYSIS$77,744
M01 · FY2008 · RR · contact PI
RENAL GLUCOSE PRODUCTION TO TOTAL GLUCOSE OUTPUT IN PATIENTS$5,310
M01 · FY2008 · RR · contact PI
EFFECTS OF INSTRUCTION ON METABOLIC RISK FACTORS ON LIFESTYLE CHOICES$4,551
M01 · FY2008 · RR · contact PI
THE ROLE OF FATTY ACID COMPOSITION IN RACIAL AND ETHNIC DIFFERENCES IN DM2$202,262
M01 · FY2007 · RR · contact PI
RISK FACTOR ANALYSIS$73,039
M01 · FY2007 · RR · contact PI
EFFECT OF INTRAVENOUS 1,25-DIHYDROXY VITAMIN D ON CIRCULATING ADHESION MOLECULE$7,374
M01 · FY2007 · RR · contact PI
EFFECTS OF INSTRUCTION ON METABOLIC RISK FACTORS ON LIFESTYLE CHOICES$7,023
M01 · FY2007 · RR · contact PI
THE ROLE OF DE-NOVO LIPOGENESIS IN NON-ALCOHOL FATTY LIVER DISEASE$6,321
M01 · FY2007 · RR · contact PI
RENAL GLUCOSE PRODUCTION TO TOTAL GLUCOSE OUTPUT IN PATIENTS$2,107
M01 · FY2007 · RR · contact PI
Institutional Clinical /Translational Science Awards$216,956
P20 · FY2006 · RR · contact PI
PLANNING GRANTS FOR INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDS$216,956
P20 · FY2006 · RR · contact PI
THE ROLE OF FATTY ACID COMPOSITION IN RACIAL AND ETHNIC DIFFERENCES IN DM2$158,408
M01 · FY2006 · RR · contact PI
RISK FACTOR ANALYSIS$63,553
M01 · FY2006 · RR · contact PI
EFFECTS OF INSTRUCTION ON METABOLIC RISK FACTORS ON LIFESTYLE CHOICES$13,280
M01 · FY2006 · RR · contact PI
THE ROLE OF DE-NOVO LIPOGENESIS IN NON-ALCOHOL FATTY LIVER DISEASE$7,273
M01 · FY2006 · RR · contact PI
EFFECT OF INTRAVENOUS 1,25-DIHYDROXY VITAMIN D ON CIRCULATING ADHESION MOLECULE$5,059
M01 · FY2006 · RR · contact PI
RENAL GLUCOSE PRODUCTION TO TOTAL GLUCOSE OUTPUT IN PATIENTS$949
M01 · FY2006 · RR · contact PI
THE ROLE OF FATTY ACID COMPOSITION IN RACIAL AND ETHNIC DIFFERENCES IN DM2$111,035
M01 · FY2005 · RR
RISK FACTOR ANALYSIS$87,268
M01 · FY2005 · RR
THYROID HORMONE LEVELS IN CENTRAL HYPOTHYROIDISM: ARE THEY AFFECTED BY THE$3,342
M01 · FY2005 · RR
EFFECT OF INTRAVENOUS 1,25-DIHYDROXY VITAMIN D ON CIRCULATING ADHESION MOLECULE$3,342
M01 · FY2005 · RR
ROLE OF PPAR IN HEPATIC GLUCOSE TRAFFICKING IN OBESE DIAB &NON-DIAB SUBJECTS$2,228
M01 · FY2005 · RR
EFFECTS OF INSTRUCTION ON METABOLIC RISK FACTORS ON LIFESTYLE CHOICES$2,228
M01 · FY2005 · RR
RENAL GLUCOSE PRODUCTION TO TOTAL GLUCOSE OUTPUT IN PATIENTS$374
M01 · FY2005 · RR
Risk Factor Analysis$52,339
M01 · FY2004 · RR
Fatty Acid Comp. in Racial/Ethnic Diff. in type2 Diabete$40,513
M01 · FY2004 · RR
Instruction in Metabol. Risk Factors on Lifestyle Choice$13,337
M01 · FY2004 · RR
Renal Glucose Production to Total Glucose Output in Patients$2,265
M01 · FY2004 · RR
INSULIN SENSITIVITY/RESPONSIVENESS AS A CORRELATE OF MUSCLE FIBER TYPE$0
M01 · FY2001 · RR
Contribution of renal glucose production to total glucose output$0
M01 · FY2001 · RR
EFFECT OF FASTING ON GLUCONEOGENESIS &GLYCOGENOLYSIS IN PTS W/ TYPE$0
M01 · FY2001 · RR
USE OF NO PAIN NON INVASIVE GLUCOSE METER IN PATIENTS W/ DIABETES MEL$0
M01 · FY2001 · RR
CONTROL MECHANISMS OF HEPATIC GLUCOSE OUTPUT$0
M01 · FY2001 · RR
RISK FACTOR ANALYSIS--DETERMINATION OF RISK FACTORS/INSULIN RESISTANCE/MED STUD$0
M01 · FY2001 · RR
CONTROL MECHANISMS OF HEPATIC GLUCOSE OUTPUT$190,136
R01 · FY2000 · DK
Contribution of renal glucose production to total glucose output$660
M01 · FY2000 · RR
USE OF NO PAIN NON INVASIVE GLUCOSE METER IN PATIENTS W/ DIABETES MEL$648
M01 · FY2000 · RR
RISK FACTOR ANALYSIS--DETERMINATION OF RISK FACTORS/INSULIN RESISTANCE/MED STUD$648
M01 · FY2000 · RR
INSULIN SENSITIVITY/RESPONSIVENESS AS A CORRELATE OF MUSCLE FIBER TYPE$648
M01 · FY2000 · RR
EFFECT OF FASTING ON GLUCONEOGENESIS &GLYCOGENOLYSIS IN PTS W/ TYPE$648
M01 · FY2000 · RR
CONTROL MECHANISMS OF HEPATIC GLUCOSE OUTPUT$648
M01 · FY2000 · RR